<p>David Moss from Lipoxen plc in the United Kingdom aims to develop a non-live polio vaccine using liposomes to entrap and deliver defined poliovirus antigens effectively to the immune system. If successful, the project will expedite the development and global deployment of a simple, economic new polio vaccine.</p>


David Moss from Lipoxen plc in the United Kingdom aims to develop a non-live polio vaccine using liposomes to entrap and deliver defined poliovirus antigens effectively to the immune system. If successful, the project will expedite the development and global deployment of a simple, economic new polio vaccine.